At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 107 enrolled
Drug / intervention
Immunotherapeutic GSK2302025A, different formulationsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma
In Brief
A Phase 1 clinical trial evaluating Immunotherapeutic GSK2302025A, different formulations for Melanoma. Completed, enrolled 107 participants across 37 sites in 6 countries.
Detailed Summary
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic \[ASCI\]) administered as a first line treatment in patients with unresectable and progressive metastatic cutaneous melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesCzechia, France, Germany, Italy, Poland, Russia
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJul 2010
Primary CompletionFeb 2014
Study CompletionDec 2016
TodayJul 2026
First PostedJun 23, 2010
Enrollment StartJul 2, 2010
Primary CompletionFeb 11, 2014
Study CompletionDec 19, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.0 years ago
Interventions
Immunotherapeutic GSK2302025A, different formulationsbiological
Intramuscular administration